Pharmaceutical

EC fines Teva $502m over multiple sclerosis treatment Copaxone practices

The European Commission (EC) has imposed a fine of €462.6m ($502m) on Teva Pharmaceuticals Industries after investigating the company’s practices regarding the standard-of-care multiple sclerosis treatment, Copaxone.

Nov 3, 2024 - 06:00
EC fines Teva $502m over multiple sclerosis treatment Copaxone practices
The European Commission (EC) has imposed a fine of €462.6m ($502m) on Teva Pharmaceuticals Industries after investigating the company’s practices regarding the standard-of-care multiple sclerosis treatment, Copaxone.
Read the original article

Tags:

Previous Article

AbbVie and EvolveImmune Therapeutics sign oncology collaboration

Next Article

Syndax agrees funding with Royalty Pharma for Niktimvo US sales

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: ‘Internist’ is a confusing, outdated term. It’s time for a new name

Opinion: ‘Internist’ is a confusing, outdated term. It’...

Apr 13, 2023

STAT+: Generic group sues Minnesota over a drug pricing transparency law it calls an ‘unconstitutional overreach’

STAT+: Generic group sues Minnesota over a drug pricing...

Jul 6, 2023

J&J expands dermatology portfolio with $850m Proteologix acquisition

J&J expands dermatology portfolio with $850m Proteologi...

May 19, 2024